Drugs /

mov18 ige

Back to Drugs List
Associated Genetic Biomarkers

Overview

Clinical Trials

View Clinical Trials for mov18 ige

Mov18 ige has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating mov18 ige, 1 is phase 1 (1 open).

FOLR1 Expression is the most frequent biomarker inclusion criterion for mov18 ige clinical trials.

Malignant solid tumor is the most common disease being investigated in mov18 ige clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Mov18 Ige
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating mov18 ige and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Drug Categories [2]:
Therapeutic antibodies

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.